Chlamydia - Pipeline Insight, 2024

This “Chlamydia - Pipeline Insight, 2024,” report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in Chlamydia pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Chlamydia Understanding

Chlamydia: Overview

Chlamydia is a sexually transmitted infectious disease caused by the bacterium Chlamydia trachomatis. In the United States, it is the most commonly reported bacterial infection. Globally, it is the most common sexually transmitted infection. It causes an ocular infection called trachoma, which is the leading infectious cause of blindness worldwide. Chlamydia is unique among bacteria, having an infectious cycle and two developmental forms. These include the infectious form called the elementary body (EB) and the reticulate body (RB). The EB is metabolically inactive and is taken up by host cells. Within the host cell, the EB will differentiate into the metabolically active RB. The RB will then use host energy sources and amino acids to replicate and form new EB, which can then infect additional cells. C. trachomatis targets the squamocolumnar epithelial cells of the endocervix and upper genital tract in women, and the conjunctiva, urethra, and rectum in both men and women.

Chlamydia - Pipeline Insight, 2024 report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Chlamydia pipeline landscape is provided which includes the disease overview and Chlamydia treatment guidelines. The assessment part of the report embraces, in depth Chlamydia commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

• The companies and academics are working to assess challenges and seek opportunities that could influence in Chlamydia R&D. The therapies under development are focused on novel approaches to treat/improve in Chlamydia.

This segment of the Chlamydia report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Chlamydia Emerging Drugs

EVO100: Evofem BiosciencesEVO100 is an investigational candidate for the prevention of urogenital chlamydia and gonorrhea in women. The investigational drug candidate EVO100 vaginal gel is designed to reduce certain vaginal infections by: 1)Balancing vaginal pH, thereby maintaining healthy vaginal flora and creating an environment that is detrimental to the growth and proliferation of harmful bacteria. 2) Using a different mechanism of action that may help to address drug resistance concern. Currently, the drug is in Phase III stage of Clinical trial evaluation for the treatment of Chlamydial infections. The FDA previously granted EVO100 Fast Track Designation for the prevention of both chlamydia and gonorrhea, and in 2017 awarded QIDP Designation to EVO100 for the prevention of gonorrhea in women.

Chlamydia: Therapeutic Assessment

This segment of the report provides insights about the different Chlamydia drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Chlamydia

There are approx. 5+ key companies which are developing the therapies for Chlamydia. The companies which have their Chlamydia drug candidates in the most advanced stage, i.e. Phase III include, Evofem Biosciences.

Phases

This report covers around 5+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Route of Administration

Chlamydia pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Parenteral
• Intravenous
• Subcutaneous
• Topical

Molecule Type

Products have been categorized under various Molecule types such as

• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy

Product Type
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Chlamydia: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Chlamydia therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Chlamydia drugs.

Chlamydia Report Insights

• Chlamydia Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Chlamydia Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Chlamydia drugs?
• How many Chlamydia drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Chlamydia?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Chlamydia?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Chlamydia and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Evofem Biosciences
• Melinta Therapeutics
• AEterna Zentaris
• Sanofi
• Spixia Biotechnology
• LinKinVax

Key Products

• EVO100
• Solithromycin
• Chlamydia vaccine
• Antibacterial therapeutic
• Chlamydia vaccine
• Anti CD40 chlamydia vaccine

This product will be delivered within 2 business days.